Kenneth Sumida, MD
Hematology & Oncology · Honolulu, HINPI 1437126380
Payments from drug & device makers
What this record shows
13 manufacturers reported payments, led by Pfizer at 37.3% of the total.
Across 48 payments — averaging $48.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$867
- US Oncology Corporate, Inc.$540
- Gilead$268
- Exelixis Inc.$259
- E.r. Squibb & Sons, L.L.C.$129
- Mckesson Specialty Care Distribution, LLC$64
- plus $196 from 7 others
Across 12 payments — averaging $16,317 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$196K
What the payments were for
- Food & beverage$1,24053%
- Education$1,08247%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 22 | $867 |
| US Oncology Corporate, Inc. | 4 | $540 |
| Gilead(2 entities) | 3 | $268 |
| Exelixis Inc. | 3 | $259 |
| E.r. Squibb & Sons, L.L.C. | 4 | $129 |
| Mckesson Specialty Care Distribution, LLC | 1 | $64 |
| Beigene USA, Inc. | 2 | $41 |
| Acrotech Biopharma Inc. | 3 | $40 |
| Bristol Myers Squibb | 2 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| AbbVie | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,322 in reported general payments places this provider in the 60th percentile of 42 hematology & oncology providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 24 | $899,505 |
| IbrancePalbociclib | 46 | $718,139 |
| TagrissoOsimertinib Mesylate | 34 | $609,364 |
| VerzenioAbemaciclib | 30 | $450,875 |
| BesremiRopeginterferon Alfa-2b-Njft | 23 | $381,962 |
| JakafiRuxolitinib Phosphate | 31 | $374,065 |
| XtandiEnzalutamide | 21 | $295,650 |
| FruzaqlaFruquintinib | 11 | $267,851 |
| CalquenceAcalabrutinib Maleate | 17 | $265,087 |
| BrukinsaZanubrutinib | 20 | $263,593 |
| PromactaEltrombopag Olamine | 23 | $228,122 |
| InqoviDecitabine/Cedazuridine | 24 | $199,382 |
| RevlimidLenalidomide | 11 | $197,822 |
| VenclextaVenetoclax | 11 | $161,993 |
| Imatinib Mesylate | 27 | $146,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $259 | $899,50524 claims |
| PfizerIbrance, Eliquis | $867 | $755,98498 claims |
| Beigene USA, Inc.Brukinsa | $41 | $263,59320 claims |
| NovartisPromacta | $15 | $228,12223 claims |
| AbbVieVenclexta, Creon | $22 | $203,27031 claims |
| Bristol Myers SquibbRevlimid | $33 | $197,82211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 42 hematology & oncology providers in Hawaii.
Other hematology & oncology in Honolulu
- Tamie KernsHonolulu$48K
- David TamuraHonolulu$31K
- Melvin PalalayHonolulu$20K
- Ryon NakasoneHonolulu$20K
- Arnold YeeHonolulu$17K
- Jared AcobaHonolulu$15K
- Swaty AroraHonolulu$15K
- William LouiHonolulu$12K
- Jodi KagiharaHonolulu$7K
- Nicolas VillanuevaHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.